Ad-ΔB + interleukin-12

**Ad-ΔB + interleukin-12** is an investigational combination therapy designed for cancer immunotherapy, leveraging a tumor-targeted, genetically engineered adenovirus (Ad-ΔB) to deliver the cytokine **interleukin-12 (IL-12)** directly to tumor cells. The Ad-ΔB vector is typically a modified oncolytic adenovirus with deletion of the E1B gene, enhancing cancer selectivity and safety. IL-12 is a potent pro-inflammatory cytokine that activates cytotoxic T cells and natural killer (NK) cells, aiming to induce a localized and systemic antitumor immune response with reduced off-target toxicity compared to systemic IL-12 administration. Preclinical studies have demonstrated the efficacy of adenoviral IL-12 delivery in tumor regression, immune profile transformation to Th1/cytotoxic states, and suppression of metastasis, with a more favorable safety profile than non-targeted IL-12 therapies. Ad-ΔB-based gene therapy platforms represent a novel strategy to overcome the historic challenge of IL-12-related toxicity by restricting expression to tumor sites and/or direct local delivery[4].